Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    pediatric neurofibromatosis brain tumor
Show Display Options
Rank Status Study
1 Active, not recruiting NF1 Brain Tumor Genetic Risk
Conditions: Neurofibromatosis Type 1;   Pediatric Brain Tumor
Intervention:
2 Active, not recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Glioma;   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
3 Recruiting Pomalidomide in Treating Younger Patients With Recurrent, Progressive or Refractory Central Nervous System Tumors
Conditions: Neurofibromatosis Type 1;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Pomalidomide
4 Completed Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Condition: Cancer
Intervention:
5 Completed
Has Results
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib
6 Recruiting Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
Conditions: Low-Grade Gliomas;   Malignant Neoplasms, Brain;   Soft Tissue Neoplasms
Intervention: Drug: MEK162
7 Enrolling by invitation Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Conditions: Ewing Sarcoma;   Osteosarcoma;   Neuroblastoma;   Acute Lymphoblastic Leukemia;   Neurofibromatosis Type 1
Intervention:

Study has passed its completion date and status has not been verified in more than two years.